China NT Pharma Group Company Limited (HKG:1011)

HKG:1011 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	24.16	37.96	7.37	-	226.7
Revenue Growth (YoY)	-36.36%	415.34%	-	-	2.24%
Cost of Revenue	14.55	32.7	-	-	81.24
Gross Profit	9.61	5.26	7.37	-	145.46
Selling, General & Admin	21.97	18.49	63.57	22.62	229.19
Operating Expenses	21.97	18.49	63.57	26.54	238.93
Operating Income	-12.36	-13.23	-56.21	-26.54	-93.47
Interest Expense	-27.84	-31.54	-28.82	-39.37	-88.73
Interest & Investment Income	-	0.01	0.01	0.04	0.24
Earnings From Equity Investments	-	10.24	37.04	9	34.49
Currency Exchange Gain (Loss)	-	-	-	-	6.66
Other Non Operating Income (Expenses)	-0.13	-6.06	0.26	0.5	6.5
EBT Excluding Unusual Items	-40.33	-40.58	-47.71	-56.37	-134.32
Merger & Restructuring Charges	-	-	-	-	-1.4
Gain (Loss) on Sale of Investments	14.08	-5.92	-	-0.63	-6.04
Gain (Loss) on Sale of Assets	-	-7.01	12.29	-	41.04
Legal Settlements	-	-	-	-	-40.63
Other Unusual Items	-	0.03	2.05	6.95	-7.4
Pretax Income	-26.26	-53.48	-33.37	-50.04	-148.75
Income Tax Expense	-	-0.12	0.12	-	2.58
Earnings From Continuing Operations	-26.26	-53.36	-33.49	-50.04	-151.33
Earnings From Discontinued Operations	-	-	-110.1	-16.37	-
Net Income to Company	-26.26	-53.36	-143.59	-66.41	-151.33
Minority Interest in Earnings	0.21	-	-	-	1.8
Net Income	-26.04	-53.36	-143.59	-66.41	-149.54
Net Income to Common	-26.04	-53.36	-143.59	-66.41	-149.54
Shares Outstanding (Basic)	31	264	239	190	189
Shares Outstanding (Diluted)	31	264	239	190	189
Shares Change (YoY)	-88.29%	10.72%	25.59%	0.51%	0.14%
EPS (Basic)	-0.84	-0.20	-0.60	-0.35	-0.79
EPS (Diluted)	-0.84	-0.20	-0.60	-0.35	-0.79
Free Cash Flow	-	-9.24	39.74	31.72	-135.98
Free Cash Flow Per Share	-	-0.04	0.17	0.17	-0.72
Gross Margin	39.78%	13.86%	100.00%	-	64.16%
Operating Margin	-51.18%	-34.84%	-763.07%	-	-41.23%
Profit Margin	-107.80%	-140.56%	-1949.36%	-	-65.96%
Free Cash Flow Margin	-	-24.35%	539.55%	-	-59.98%
EBITDA	-12.32	-13.18	-51.63	-9.39	-57.27
EBITDA Margin	-50.98%	-34.72%	-	-	-25.26%
D&A For EBITDA	0.05	0.05	4.58	17.16	36.2
EBIT	-12.36	-13.23	-56.21	-26.54	-93.47
EBIT Margin	-51.18%	-34.84%	-	-	-41.23%
Advertising Expenses	-	-	-	-	141.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.